123 results
Page 2 of 7
8-K
EX-99.1
jv8q g4if0x664
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
EX-99.1
cxgwywh
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
424B5
mjtdoq6cn76ct7t
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
rumldc3fn5hkmrti
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
6x1v l3zc
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
h9lucca6h ha4bz1i2t
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
ypj8shot
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
424B3
loq1n9l9w 14y4xts
19 Jan 22
Prospectus supplement
4:05pm
8-K
42ysi4r u7zdishx
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
qrj4 3l1x1yr2yop
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
de8l2 ofq9k2sfjh7u2
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
cntqhdrs
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
i2l0je xeig
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
r6auljr144qi xfqfy
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
tc8jo
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am